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Abstract
We have attempted to simplify the procedure for coupling various ligands to distal ends of liposome-grafted polyethylene
glycol (PEG) chains and to make it applicable for single-step binding of a large variety of a primary amino group-containing
substances, including proteins and small molecules. With this in mind, we have introduced a new amphiphilic PEG
derivative, p-nitrophenylcarbonyl-PEG-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (pNP-PEG-DOPE), synthesized by
reaction of DOPE with excess of bis(p-nitrophenylcarbonyl)-PEG in a chloroform/triethylamine mixture. pNP-PEG-DOPE
readily incorporates into liposomes via its PE residue, and easily binds primary amino group-containing ligands via its water-
exposed pNP groups, forming stable and non-toxic urethane (carbamate) bonds. The reaction between the pNP group and
the ligand amino group proceeds easily and quantitatively at pH around 8.0, and remaining free pNP groups are promptly
eliminated by spontaneous hydrolysis. Therefore, pNP-PEG-DOPE could serve as a very convenient tool for protein
attachment to the distal ends of liposome-grafted PEG chains. To investigate the applicability of the suggested protocol for
the preparation of long-circulating targeted liposomes, we have coupled several proteins, such as concanavalin A (ConA),
wheat germ agglutinin (WGA), avidin, monoclonal antimyosin antibody 2G4 (mon2G4), and monoclonal antinucleosome
antibody 2C5 (mon2C5) to PEG-liposomes via terminal pNP groups and studied whether the specific activity of these
immobilized proteins is preserved. The method permits the binding of several dozens protein molecules per single 200 nm
liposome. All bound proteins completely preserve their specific activity. Lectin-liposomes are agglutinated by the appropriate
polyvalent substrates (mannan for ConA-liposomes and glycophorin for WGA-liposomes); avidin-liposomes specifically
bind with biotin-agarose; antibody-liposomes demonstrate high specific binding to the substrate monolayer both in the direct
binding assay and in ELISA. A comparison of the suggested method with the method of direct membrane incorporation was
made. The effect of the concentration of liposome-grafted PEG on the preservation of specific protein activity in different
coupling protocols was also investigated. It was also shown that pNP-PEG-DOPE-liposomes with and without attached
ligands demonstrate increased stability in mouse serum. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes have long been considered promising
pharmaceutical carriers in vivo [1,2] and have already
found their way into a real clinical practice [3^5]. It
was believed that the use of targeted liposomes, i.e.
liposomes with a speci¢c a⁄nity for the a¡ected or-
gan or tissue, should increase the e⁄cacy of the lipo-
somal pharmaceutical agents [6]. To target liposomal
pharmaceuticals to organs other than the liver and
spleen, liposomes have been modi¢ed with speci¢c
targeting moieties (antibodies) [7]. However, similar
to ‘plain’ liposomes, immunoliposomes also do not
exhibit prolonged circulation and fail to accumulate
su⁄ciently in targets with diminished blood supply
and/or low antigen concentration [8,9].
On the other hand, to make liposomes capable of
delivering pharmaceutical agents to targets other
than the reticulo-endothelial system, attempts have
been made to prolong their lifetime in the circula-
tion. Such long-circulating liposomes were expected
to accumulate in various areas with ‘leaky’ vascula-
ture, such as infarcts and tumors [8^12], via the so-
called enhanced permeability and retention (EPR)
e¡ect [13,14]. The problem of how to achieve long
circulation was solved with the development of poly-
mer-coated liposomes with decreased opsonization
rate and sharply increased circulation times (steri-
cally protected liposomes, ‘stealth’ liposomes, long-
circulating liposomes) [15]. Alternatively, it was re-
peatedly shown that small liposomes also possess an
increased longevity compared to liposomes of a larg-
er size [16^19]. However, since the entrapment ca-
pacity of liposomes for drugs strongly diminishes
with decrease of liposome size, larger polymer-coated
liposomes were considered more promising pharma-
ceutical carriers. The usual preparation method of
such liposomes includes liposome coating with poly-
(ethylene glycol) or PEG [20^22], though some other
polymers can also be successfully used [23^27].
Further development of the concept of long-circu-
lating liposomes involves the attempt to combine the
properties of long-circulating liposomes and immu-
noliposomes in a single preparation [8,9]. Such an
approach is especially important for e⁄cient targeted
delivery of liposomal drugs to targets with dimin-
ished blood supply and/or low antigen concentration,
when increased circulation times for e⁄cient lipo-
some-to-target interaction are required. This ap-
proach requires the simultaneous presence of both
the protecting polymer and the targeting moiety
(usually a monoclonal antibody or its fragment) on
the liposome surface.
It is evident that the protective polymer may create
steric hindrances for target recognition with the tar-
geting moiety if simple co-incorporation of an anti-
body and protecting polymer into the liposome mem-
brane is performed [28^30], though those hindrances
can be overcome by thorough selection of a ratio
(relative quantity) of protective polymer and target-
ing moiety on the liposome surface. Using this ap-
proach, we were able to achieve e¡ective targeting of
long-circulating immunoliposomes into infarcted my-
ocardium in vivo [8]. On the other hand, the target-
ing moiety can be attached above the protecting
polymer layer, for example, by coupling it with the
distal end of an activated liposome-grafted polymer
molecule. Several protocols were developed to pre-
pare PEG and other polymers which contain both a
hydrophobic group at one end and a reactive group
on the other end, and to attach antibodies to such
polymers on liposomes [31^37]. Thus, maleimide-de-
rivatized antibody was coupled to liposome surface-
attached PEG containing thiol groups on its distal
termini [32,33]. A comparison was made in [31,32]
between liposomes with antibody and polymer co-
incorporated into the membrane and liposomes
with antibody attached to PEG termini, which
clearly demonstrated better characteristics (binding
e⁄cacy, association with target cells) of immunolipo-
somes with PEG termini-attached antibodies. Similar
results were obtained with partially oxidized antibod-
ies coupled to the PEG terminus through a terminal
hydrazide group [34]. Antibodies were also coupled
to terminal carboxylic groups of amphiphilic PEG
via water-soluble carbodiimide [35]. In [36], long-cir-
culating immunoliposomes were prepared by anti-
body attachment to PEG end groups functionalized
with cyanuric chloride. All mentioned protocols,
though quite e¡ective, require a separate step of anti-
body pre-modi¢cation or involve the use of toxic
intermediates.
To further simplify the coupling procedure and to
make it applicable for single-step binding of a large
variety of amino group-containing ligands (including
antibodies, proteins and small molecules) to the dis-
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tal end of liposome-attached polymeric chains with-
out the use of any potentially toxic compounds, we
have introduced a new amphiphilic PEG derivative,
p-nitrophenylcarbonyl-PEG-PE (pNP-PEG-PE) [38].
pNP-PEG-PE readily incorporates into liposomes via
its phospholipid residue, and easily binds any amino
group-containing compound via its water-exposed
pNP group forming a stable and non-toxic urethane
(carbamate) bond [39,40]. The use of a similar car-
bamate linker for the attachment of amino acids via
their N-termini to (hydroxymethyl)polystyrene was
also described in [41]. The reaction between the
pNP group and the ligand amino group proceeds
easily and quantitatively at pH around 8.0, while
excessive free pNP groups are easily eliminated by
spontaneous hydrolysis. The current study has been
undertaken to further investigate the e⁄cacy of pro-
tein binding to pNP-PEG-PE-containing liposomes,




Egg phosphatidylcholine (PC), cholesterol (Chol),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE), polyoxyethylene(MW 2000)-DOPE (PEG-
DOPE), stearylamine, and N-glutaryl phosphatidyl-
ethanolamine (NGPE) were from Avanti Polar Lip-
ids. Concanavalin A (ConA), wheat germ agglutinin
(WGA), avidin, biotin-agarose, glycophorin, K-meth-
yl mannoside, L-fucose, diaminobutane, p-nitrophe-
nol, triethylamine (TEA), octyl glycoside (OG), di-
ethylenetriaminepentaacetic acid anhydride (DTPA),
mannan from Saccharomyces cerevisiae, and poly-
oxyethylene(MW 3500)-bis(p-nitrophenyl carbonate)
(PEG-(pNP)2) were products of Sigma. 1-Ethyl-3-(3P-
dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysulfosuccinimide (NHS) were from Pierce.
111InCl3 was obtained from NEN. All solvents and
components of bu¡er solutions were analytical grade
products.
Cell lines producing cardiac myosin-speci¢c mono-
clonal antibody 2G4 (mon2G4) [42,43] and nucleo-
some-speci¢c monoclonal antibody 2C5 (mon2C5)
[44,45] (both belonging to the immunoglobulin
(IgG) class) are available in our laboratory. Mono-
clonal antibodies were puri¢ed from corresponding
murine ascites according to the standard methods
of ammonium sulfate precipitation, DEAE-cellulose
anion exchange chromatography, and chromatofo-
cusing over a pH gradient of 7.0^5.0. The purity of
antibody preparations was characterized by gel elec-
trophoresis and HPLC. Since mon2C5 is very sensi-
tive to various chemical modi¢cations, this antibody
was protected from inactivation by reversible com-
plexation with dextran sulfate (Samokhin et al., to be
published elsewhere) for all attachment and labeling
procedures.
2.2. Methods
2.2.1. Synthesis of pNP-PEG-DOPE
24 mg (32.2 Wmole) of DOPE was dissolved in
chloroform to obtain a 50 mg/ml solution. The solu-
tion was supplemented with 80 Wl (approx. 2-fold
molar excess over PEG-(pNP)2) of TEA. 1 g (ap-
prox. 10-fold molar excess over DOPE) of PEG-
(pNP)2 dissolved in 5 ml of chloroform was added
to the mixture and the sample was incubated over-
night at room temperature with stirring under argon.
Then, the organic solvents were removed using a
rotary evaporator. The pNP-PEG-DOPE micelles
were formed in 0.01 M HCl, 0.15 M NaCl using
water bath sonication. The micelles were separated
from the unbound PEG and released pNP on a CL-
4B column using 0.01 M HCl, 0.15 M NaCl as an
eluent. Pooled fractions containing pNP-PEG-DOPE
were freeze-dried, and pNP-PEG-DOPE was ex-
tracted with chloroform. The latter procedure was
repeated twice to ensure the complete removal of
NaCl from the preparation. pNP-PEG-DOPE was
stored as chloroform solution at 380‡C.
2.2.2. Liposome preparation
Liposomes were prepared by detergent (OG) re-
moval from a mixture of egg phosphatidylcholine
and cholesterol (7:3 molar ratio). The starting lipid
mixture in chloroform was argon-dried, vacuumed,
solubilized with OG in HEPES-bu¡ered saline
(HBS), pH 7.4 (¢nal total lipid concentration may
vary from 5 to 20 mg/ml), and dialyzed overnight
against HBS at 4‡C. Liposomes obtained were sized
by repeated passing through the polycarbonate ¢lters
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with gradually decreasing pore size, 0.6, 0.4 and 0.2
Wm (Nuclepore). When necessary, the initial lipid
mixture was supplemented with various quantities
of PEG-DOPE, pNP-PEG-DOPE, or their mixture
in a required molar ratio. When PEG-DOPE- and/or
pNP-PEG-DOPE-containing liposomes were pre-
pared, the lipid/polymer ¢lm was dissolved in citrate,
pH 5.1 (slightly acidic pH prevents the pNP residue
from fast hydrolysis) with an excess of OG, and the
solution was dialyzed against Na-citrate. Addition-
ally, 1 mol% of DTPA-stearylamine (DTPA-SA)
was added to all lipid compositions, when subse-
quent radiolabeling of liposomes with 111In was re-
quired.
2.2.3. Preparation of radioactive labels and labeling of
liposomes with 111In
When necessary, liposomes were radioactively la-
beled with 111In via the liposome-incorporated am-
phiphilic chelating agent DTPA-SA. DTPA-SA was
synthesized according to recommendations of [46]
with some changes. Brie£y, 1.55 g of SA and 2.5 g
of DTPA cyclic anhydride were mixed with 250 ml of
dry chloroform. The mixture was re£uxed for 1 h,
the top outlet of the system being coated with foil.
Then, 3 ml of TEA was added, and the mixture was
re£uxed for an additional 48 h. Chloroform was
evaporated on a rotary evaporator, its traces were
removed by heating with water at 50‡C. 100 ml of
0.1 N HCl was added to the dry product, and the
mixture was stirred with heating at 80‡C for 10 min
and incubated overnight at room temperature. The
precipitate was separated by centrifugation, washed
three times with 100 ml of 0.1 N HCl with stirring
and then lyophilized. The lyophilized product was
washed twice with 100 ml of methanol, and then
recrystallized twice from boiling methanol and dried.
To label DTPA-SA-containing liposomes with 111In,
the liposomal suspension (normally, 2 ml) was sup-
plemented with 30 Wl of 1.0 M Na-citrate and incu-
bated for 1 h with a required quantity of citrate
complex of 111In (added as InCl3) at room temper-
ature, and then dialyzed overnight against HBS at
4‡C to remove unbound 111In.
2.2.4. Characterization of liposomes
Liposome size and size distribution were deter-
mined immediately after preparation using a stan-
dard method of dynamic light scattering with a
Coulter N4+ MD Submicron Particle Size Analyzer
(Coulter Electronics). For all polymer-containing
liposomes, the e⁄cacy of polymer incorporation
into the liposomal membrane was monitored by gel
chromatography and/or HPLC in order to check for
possible formation and presence of micelles com-
posed of free non-incorporated polymer. The separa-
tion is based on the fact that the size of micelles is
usually within the 15^60 nm limits, whereas lipo-
somes are approx. 150 nm and up in size.
2.2.5. Proteins
Proteins that were attached to liposomes in our
experiments by interaction with the pNP group of
liposome-incorporated pNP-PEG-DOPE or by pre-
liminary modi¢cation of antibodies with a hydropho-
bic residue of NGPE [47] and subsequent co-incor-
poration into liposomes together with PEG-DOPE
include ConA, WGA, avidin, mon2G4, and
mon2C5.
2.2.6. Antibody modi¢cation with NGPE
For incorporation directly into the liposomal
membrane, mon2G4 and mon2C5 antibodies were
preliminarily modi¢ed with the hydrophobic ‘an-
chor’, NGPE, as described in [47]. Brie£y, 0.3 mg
of NGPE were dried with argon from chloroform
solution and then solubilized in 0.5 ml of 0.016 M
OG in 50 mM MES. The solution was supplemented
with 12 mg of EDC and 15 mg of NHS. The mixture
was incubated for 5 min and then added to the so-
lution of 2 mg of the antibody in 0.1 M HEPES, pH
7.6. pH was adjusted to 8.0 with 1 M NaOH, and the
mixture was incubated overnight at 4‡C. The modi-
¢ed antibody was puri¢ed by dialysis in a Spectrum
dialysis bag (MWCO 1000) overnight against HBS at
4‡C and stored at the same temperature until use.
2.2.7. Attachment of proteins to liposomes
To attach proteins to liposomes, two di¡erent pro-
tocols were used. According to one protocol, protein
was pre-modi¢ed with NGPE and then hydrophobi-
cally anchored into the liposomal membrane during
liposome preparation [8,9,47]. This protocol was
used with mon2G4 and mon2C5 only. In this case,
NGPE-modi¢ed antibody (‘cold’ or 111In-labeled)
was added to the dried lipid or lipid/polymer ¢lm
BBAMEM 78083 22-3-01
V.P. Torchilin et al. / Biochimica et Biophysica Acta 1511 (2001) 397^411400
of a required composition (approx. 1 mg of modi¢ed
protein per 10 mg of lipid or lipid/polymer mixture)
in OG-containing solubilization bu¡er. In the pro-
cess of detergent dialysis and liposome formation,
NGPE antibody was quantitatively anchored into
the membrane via the hydrophobic NGPE group
[8,9]. Antibody incorporation into the membrane is
usually quantitative. However, liposomes were addi-
tionally puri¢ed by gel ¢ltration on Sepharose CL-6B
to exclude any non-incorporated antibody from the
preparation.
Alternatively, non-modi¢ed proteins (ConA,
WGA, avidin, mon2G4, and mon2C5) were attached
via pNP groups to the distal ends of liposome-
grafted DOPE-PEG-pNP chains. For this purpose,
proteins were added (approx. 1 mg of protein per
10 mg of lipid/polymer mixture) to pNP-PEG-
DOPE-containing liposomes stored at pH 5.1 (Na-
citrate bu¡er), and pH was raised to 8.5. Incubation
for about 2 h resulted in a su⁄cient protein binding
and simultaneous hydrolysis of non-reacted pNP
groups. Protein-containing liposomes were puri¢ed
by gel ¢ltration on a Bio-Gel A15M column.
2.2.8. Determination of the rate of hydrolysis and
chemical conversion of the p-nitro-
phenylcarbonyl group in pNP-PEG-DOPE
To investigate a comparative rate of hydrolysis
and chemical conversion of pNP groups in pNP-
PEG-DOPE, a suspension of pNP-PEG-DOPE mi-
celles with a concentration of 0.4 mg/ml was pre-
pared by addition of 10 mM Na-citrate, 140 mM
NaCl, pH 4.0 (CBS) to the dried ¢lm of pNP-
PEG-DOPE and extensive vortexing. After vortexing
in citrate bu¡er, the lipid-modi¢ed polymer formed a
transparent system typical for micelles. A 0.5 ml ali-
quot of the micellar suspension obtained was mixed
with 1.5 ml of 2 mM diaminobutane (DAB, a model
amino-containing compound capable of chemical in-
teraction with pNP groups) in 100 mM borax, 140
mM NaCl, pH 8.5 (BBS), or with DAB-free BBS
within 10 min after the preparation of micelles in
CBS. The releasing p-nitrophenol (pNP) was regis-
tered spectrophotometrically at 405 nm (OD405),
with suspensions of the micelles prepared from
DOPE-PEG-OH in CBS/BBS with or without DAB
used as the blanks (all concentrations were the same
as in working suspensions). The molar concentration
of the pNP released during the hydrolysis or cou-
pling reactions at di¡erent time points was calculated
from OD405 values using a standard 10 mM pNP
solution diluted with the appropriate bu¡er mixtures.
2.2.9. Radiolabeling of proteins with 111In and
determination of the quantity of liposome-bound
proteins
To estimate the quantity of a protein bound to a
single liposome, proteins (non-modi¢ed or, in the
case of mon2G4 and mon2C5 antibodies, after the
modi¢cation with NGPE) were preliminarily radio-
labeled with 111In. For this purpose, all proteins were
initially modi¢ed with DTPA using the DTPA anhy-
dride according to [48]. Aliquots of protein solutions
(5^10 mg/ml) in 0.1 M NaHCO3 pH 8.0 were sup-
plemented with 50^100-fold molar excess of DTPA
anhydride. After overnight incubation at 4‡C, sam-
ples were dialyzed against a large excess of 0.1 M
Na-phosphate bu¡er pretreated with Chelex-100 at
1 g resin per liter to better ensure removal of any
contaminating trivalent cations. If necessary, the
number of moles of DTPA covalently linked to a
given protein may be assessed by TNBS assay to
determine free amino groups of a protein [49].
Then, all DTPA-modi¢ed proteins were labeled
with 111In using citrate at pH 5.5^6 as the transche-
lator. For this purpose, 100 Wg of DTPA-protein was
supplemented with 1 mCi of 111InCl3 in 0.1 M Na-
citrate, pH 5.5, and incubated at room temperature
for 30 min. Free 111In was removed from the labeled
protein by Sephadex G-10 column chromatography
or by dialysis against a large volume of HBS. The
radioactivity bound with the protein was then deter-
mined. Since the quantities of protein and lipid were
always known, as well as the number of phospholip-
id molecules forming a liposome of a given size [50],
we could estimate the exact quantity of a given pro-
tein associated with a single liposome by measuring
the liposome-associated 111In radioactivity after pro-
tein attachment to liposomes (whatever attachment
protocol was used) and removal of non-bound pro-
tein.
2.2.10. Agglutination of lectin-containing liposomes
The carbohydrate binding activities and speci¢c-
ities of liposome-attached lectins were examined us-
ing an aggregation assay [51]. The multivalent sub-
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strates for ConA (mannan) or WGA (glycophorin)
were dissolved in PBS bu¡er at di¡erent concentra-
tions and 100 Wl aliquots of the solution obtained
were added to suspensions of lectin-containing lipo-
somes (total lipid concentration was adjusted to ap-
prox. 1 mg/ml). The mixtures were vortexed, incu-
bated for 20 min at room temperature and then
transferred to the UV/VIS spectrophotometer. Lipo-
some aggregation was followed by the turbidity (op-
tical density, OD) increase at 400 nm. The preserva-
tion of carbohydrate speci¢city of liposome-bound
lectins was examined by the same agglutination assay
after the incubation of the lectin-bearing liposomes
with 100 Wmol of corresponding inhibitors (K-methyl
mannoside for ConA-liposomes and L-fucose for
WGA-liposomes).
2.2.11. Binding of avidin-liposomes to biotin-agarose
To examine the preservation of the speci¢c binding
activity of the liposome-attached avidin to biotin, we
have used a binding assay on biotin-agarose. For this
purpose, pNP-PEG-DOPE-containing 111In-labeled
liposomes (see above) with attached avidin were ap-
plied to the column of biotin-agarose and eluted with
HBS. After elution, the column was additionally
washed with a large volume of HBS, and then the
radioactivity remaining associated with the column
was measured. 111In-labeled PC:Chol liposomes, pro-
tein-free pNP-PEG-DOPE-liposomes (after complete
hydrolysis of pNP) and pNP-PEG-DOPE-liposomes
with attached ConA were used as controls.
2.2.12. Determination of antibody-liposome immuno-
reactivity by direct binding of radiolabeled
antibody-liposome with antigen monolayer
To determine the preservation of the speci¢c
activity of pNP-PEG-DOPE-liposome-associated
mon2G4, we estimated the direct binding of 111In-
labeled mon2G4-bearing liposomes with a monolayer
of a corresponding antigen: dog cardiac myosin
[42,43]. Antigen-coated microtiter plates were pre-
pared following the same procedure as was used
for the ELISA protocol (see below). Mon2G4-bear-
ing 111In-labeled liposomes were added to the anti-
gen-coated wells. The maximum count used per 50 Wl
aliquot was 2U106 cpm. The reaction was allowed to
proceed until equilibrium, for 4 h at room temper-
ature or overnight at 4‡C. The wells were extensively
washed to remove loosely bound radioactivity, cut
and counted in a Q-scintillation counter for 111In ac-
tivity. The binding of 111In-labeled mon2G4-lipo-
somes was compared with the binding of 111In-la-
beled PC:Chol liposomes, protein-free pNP-PEG-
DOPE-liposomes (after complete hydrolysis of pNP
groups), and mon2C5-liposomes.
2.2.13. Immunological activity of free, modi¢ed and
liposome-attached antibodies
Generally, the immunological activity of starting
antibodies, NGPE-modi¢ed antibodies, and antibod-
ies attached to the liposome surface by two di¡erent
methods was tested by sandwich ELISA. For the
myosin-antimyosin assay, 96-well U-bottomed mi-
crotiter plates were coated with 50 Wl of 10 Wg/ml
dog cardiac myosin overnight at 4‡C. Plates were
washed three times with PBS containing 0.05%
Tween (PBST, pH 7.4) and blocked with 10% heat-
inactivated horse serum albumin to saturate the re-
maining non-speci¢c binding surfaces and minimize
non-speci¢c binding. Serial 10-fold dilutions of vari-
ous preparations were added to the wells and incu-
bated at 37‡C for 1 h. The plates were then washed
three times and HRP-tagged goat anti-mouse IgG
was added to each well. The plates were again incu-
bated at 37‡C for 1 h and washed with PBST. The
bound material was revealed by treating with o-phen-
ylenediamine hydrochloride as a colored substrate in
citrate bu¡er and OD was read on an ELISA reader
at 405 nm. ELISA for nucleosome-antinucleosome
antibody was similarly carried out in microtiter
plates coated with nucleohistone at 10 Wg/ml. All
other steps were as described above.
2.2.14. Stability of calcein-loaded liposomes in mouse
serum
Liposomes for serum-provoked destabilization ex-
periments were prepared by sonication. A solution of
a mixture of PC:Chol (7:3 molar ratio) in chloro-
form and a required quantity of PEG-DOPE or
pNP-PEG-DOPE was dried under argon and addi-
tionally freeze-dried using a Freezone 4.5 Freeze Dry
System (Labconco). The ¢lm obtained was hydrated
with 60 mM calcein solution (self-quenching concen-
tration) in HBS, pH 7.4. After sonicating the mixture
using a bath-type sonicator (Laboratory Supplies)
for 10 min, the calcein-loaded liposomes were sepa-
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rated from free calcein by column chromatography
(Sephadex G-25; 0.8U5.2 cm), and additionally dia-
lyzed overnight at 4‡C against HBS. In case when
mon2C5-pNP-PEG-DOPE-liposomes were obtained,
60 mM calcein in Na-citrate bu¡er (pH 5.1) was used
for ¢lm hydration. After antibody attachment via
pNP groups (see above), liposomes were separated
from unbound antibody on a Sepharose CL-4B col-
umn.
Calcein-loaded liposomes of various compositions
were incubated in HBS or in HBS with 50% mouse
serum at 25‡C for certain time intervals, and the
£uorescence intensity of the released calcein was
measured using a F-2000 Fluorescence Spectropho-
tometer (Hitachi Instruments) at an excitation wave-
length of 490 nm and an emission wavelength of 530
nm. To determine the total ‘releasable’ £uorescence,
each liposomal preparation was treated by Triton X-
100 in order to destroy liposomes and release all the
intraliposomal calcein.
3. Results and discussion
3.1. Ligand attachment via free terminal p-nitro-
phenylcarbonyls and hydrolysis of non-reacted
pNP groups
The new single terminus-reactive PEG derivative,
pNP-PEG-DOPE, was synthesized according to the
general scheme presented in Fig. 1. The derivative
obtained is quite stable at slightly acidic pH values
(around 5); however, its pNP group easily interacts
with amino groups of low molecular weight and high
molecular weight ligands at pH values from 8 and
up, with the formation of a stable carbamate (ure-
thane) bond (see the reaction scheme in Fig. 2). Since
the pNP group itself undergoes hydrolysis at pH val-
ues above neutral, one has to be sure that the attach-
ment of amino group-containing ligands to the pNP
group in pNP-PEG-DOPE proceeds faster than, or
at least at a comparable rate to, pNP hydrolysis.
With this in mind, we have investigated a compara-
tive rate of hydrolysis and chemical conversion of
pNP groups in pNP-PEG-DOPE at pH 8.5. For
this purpose, pNP-PEG-DOPE micelles were pre-
pared, and the rates of pNP group spontaneous hy-
drolysis and interaction with the model amino group-
containing ligand, DAB, were determined following
the release of the free p-nitrophenol, characteristic of
both reactions. The molar concentrations of the pNP
released at di¡erent time points were calculated from
OD405 values using as a standard 10 mM solution of
the pNP.
The results obtained are presented in Fig. 3. In
both cases (in pure BBS and in BBS with DAB)
the release of free pNP followed a single exponential
function (R2s 0.99). The half-times of pNP release
Fig. 1. General reaction scheme for the synthesis of pNP-PEG-PE.
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in BBS, pH 8.5, in the presence of DAB and in BBS
alone were 20 and 31 min, respectively. It shows that
in the presence of DAB, about one third of the active
pNP groups react with the primary amino groups of
the ligand. The remaining pNP groups undergo hy-
drolysis. At higher pH values the fraction of pNP
groups reacting with primary amino groups increases
(at pH 9.3 about 65% of pNP groups bind the ligand,
while only 35% of pNP groups hydrolyze; data not
shown). The complete conversion or hydrolysis of
pNP groups at pH values above 8 takes between 1
and 2 h. It is worth mentioning that the concentra-
tion of free pNP, upon completion of the reaction,
was approx. 20 WM, which is about 85% of pNP-
PEG-DOPE concentration in the systems. It means
that at least 85 mol% of the initial polymer synthe-
sized by us, following the scheme shown in Fig. 1,
contained active pNP groups.
Concluding, pNP groups in pNP-PEG-DOPE ef-
fectively interact with the primary amino groups of a
ligand at pH values of 7.5 and above, while non-
reacted pNP groups are eliminated from the system
by spontaneous hydrolysis. The relative rates of the
coupling and hydrolysis processes can be controlled
by the pH value of the reaction system. Even at pH
values only slightly above neutral, quite a su⁄cient
number of pNP groups is available for ligand bind-
ing.
3.2. Liposome preparation and characterization;
quantitation of liposome-attached protein
The method of detergent (OG) dialysis yields prep-
arations of similar size (approx. 200 nm) and size
distribution for all types of liposomes used ^ plain
PC:Chol (7:3) liposomes, PEG-DOPE-liposomes,
pNP-PEG-DOPE-liposomes, and protein-pNP-PEG-
DOPE-liposomes (see Fig. 4) ^ as was shown by
Fig. 2. General reaction scheme for the attachment of amino group-containing ligands to the pNP group.
Fig. 3. Comparative rates of spontaneous hydrolysis of the
pNP group (2) and its interaction with the amino group-con-
taining ligand (1). Diaminobutane was used as a model reagent.
See Section 2.2 for details.
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dynamic light scattering, the most frequently used
method of liposome size determination, which pro-
vides the most consistent and accurate measurements
[52^54].
In all cases, the incorporation of polymers in lipo-
somes was complete, since HPLC did not reveal any
micelles of free polymer in the system. To estimate
the quantity of a protein bound to a single pNP-
PEG-DOPE-liposome, proteins were radiolabeled
with 111In prior to their coupling to liposomes (see
Section 2.2). Since the quantity of a protein and ra-
diolabel was always known, we could estimate the
exact quantity of a protein on the liposome surface
by measuring liposome-associated 111In radioactivity
after protein attachment to liposome and removal of
free protein. From the radioactivity data, we deter-
mined that, depending on the protein and starting
lipid-to-protein ratio, between approx. 80 and 200
protein molecules can be bound to a single 200 nm
liposome, whatever protein is used (ConA, WGA,
avidin, or an antibody). In general, the increase in
the molar fraction of pNP-PEG-DOPE in liposomes
and the increase of the protein-to-pNP ratio results
in a certain increase in the number of bound protein
molecules, when pNP-PEG-DOPE concentration in
the lipid mixture was below 1 mol%. However, at a
constant concentration of pNP-PEG-DOPE in lipo-
somes and constant protein-to-pNP ratio, no regu-
larities were found for the binding e⁄cacy of di¡er-
ent proteins. The binding yield for the same or
di¡erent proteins in separate runs usually varied by
a factor of about 2, with the total number of protein
molecules bound with a single liposome being within
the limits described above. From a practical point, it
Fig. 4. Liposome size and size distribution in di¡erent preparations. (A) Plain PC:Chol liposomes; (B) PEG(2000)-PE-coated PC:Chol
liposomes (6 mol% of PEG-PE); (C) pNP-PEG-DOPE-coated PC:Chol liposomes (6 mol% of pNP-PEG-DOPE); (D) pNP-PEG-
DOPE-coated PC:Chol liposomes (6 mol% pNP-PEG-DOPE) with attached mon2C5 coupled to distal pNP groups. See Section 2.2
for details.
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means that, even upon incubation under conditions
where some hydrolysis of pNP residues has to occur,
pNP-PEG-DOPE-modi¢ed liposomes still demon-
strate the ability to bind substantial quantities of
proteins, su⁄cient for further liposome targeting in
vivo [7]. It is important that practically the same
quantity of protein can be bound to liposomes con-
taining 6 mol% of pNP-PEG-DOPE and 6 mol% of
the mixture of PEG-DOPE and pNP-PEG-DOPE in
5:1 molar ratio. It means that even as little as ap-
prox. 1 mol% (of total lipid) of pNP-PEG-DOPE
can provide a su⁄cient number of reactive groups
on the liposome surface to bind approx. 100 protein
molecules to a single 200 nm liposome. Only when
the fraction of pNP-PEG-DOPE goes below 1 mol%,
does the quantity of an attached protein begin to
decrease.
3.3. Agglutination of lectin-pNP-PEG-DOPE-
liposomes
To investigate the preservation of the speci¢c ac-
tivity of lectins coupled to liposomes via distal pNP
groups in pNP-PEG-DOPE-liposomes, we, similar to
[51], have performed an agglutination analysis. The
turbidity changes of suspensions of lectin-liposomes
in the presence of their corresponding substrates are
presented in Fig. 5. Upon the addition of polyvalent
substrates (mannan for ConA-liposomes and glyco-
phorin for WGA-liposomes), the turbidity of the sus-
pensions increases with the increase in substrate con-
centration, indicating increasing agglutination of
lectin-liposomes. However, in the presence of lectin-
speci¢c low molecular weight competitive monova-
lent substrates (K-methyl mannoside for ConA-lipo-
somes and L-fucose for WGA-liposomes), practically
no changes in turbidity were observed, even at high
concentrations of the polyvalent substrates. At the
same time, when monovalent substrates were re-
versed (i.e. L-fucose was used with ConA-liposomes
and K-methyl mannoside with WGA-liposomes), vir-
tually no inhibition of liposome agglutination with
polyvalent substrates was observed (data not shown).
Together, these data show that both lectins immobi-
lized on pNP-PEG-DOPE-liposomes via the distal
pNP groups preserve their functional binding activity
and carbohydrate speci¢city.
3.4. Binding of avidin-pNP-PEG-DOPE-liposomes
with biotin-agarose
To prove the preservation of the speci¢c activity of
avidin coupled to liposomes via distal pNP groups in
pNP-PEG-DOPE-liposomes, we have investigated
Fig. 5. Agglutination of lectin-pNP-PEG-PE-liposomes with
and without inhibition. Agglutination of WGA-liposomes with
glycophorin: (1) in the absence of the competitive low molecu-
lar weight ligand L-fucose; (3) in the presence of excess of L-fu-
cose. Agglutination of ConA-liposomes with mannan: (2) in the
absence of the competitive low molecular weight ligand K-meth-
yl mannoside; (4) in the presence of K-methyl mannoside. See
Section 2.2 for details.
Fig. 6. 1, binding of 111In-labeled avidin-pNP-PEG-DOPE-lipo-
somes on a biotin-agarose column. Controls: 2, binding of pro-
tein-free 111In-pNP-PEG-DOPE-liposomes (after the complete
hydrolysis of pNP groups) on a biotin-agarose column; 3, bind-
ing of 111In-labeled ConA-pNP-PEG-DOPE-liposomes on a bio-
tin-agarose column. Presaturation of the biotin-agarose column
with the excess of free avidin completely abolished the binding
of avidin-liposomes (data not shown). See Section 2.2 for de-
tails.
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the binding of avidin-liposomes on a biotin-agarose
column. The data presented in Fig. 6 clearly show
that avidin-liposomes strongly bind to biotin-aga-
rose, while control avidin-free pNP-PEG-DOPE-
liposomes and pNP-PEG-DOPE-liposomes with at-
tached ConA demonstrate only marginal binding.
The speci¢city of avidin-liposome binding on bio-
tin-agarose was further con¢rmed by the fact that
pretreatment of the biotin-agarose column with an
excess of free avidin almost completely abolished
the binding of the avidin-liposomes (not shown).
Thus, similar to lectins, avidin covalently bound to
the distal tips of PEG-liposomes via pNP groups of
liposome-incorporated pNP-PEG-DOPE preserves
its functional activity and speci¢city.
3.5. Activity of liposome-bound mon2G4
The antimyosin mon2G4 was used to study
the interaction of 111In-labeled mon2G4-pNP-PEG-
DOPE liposomes with a monolayer of the antigen,
dog cardiac myosin, in a direct binding assay, as well
as for the comparison of two di¡erent methods of
antibody immobilization on liposomes ^ by direct
membrane incorporation of an antibody modi¢ed
with a hydrophobic group of NGPE [8,9,47] and
by covalent attachment of a non-modi¢ed antibody
to the distal pNP groups in pNP-PEG-DOPE-lipo-
somes. Fig. 7 presents the data of the direct binding
assay of various preparations of 111In-labeled lipo-
somes with the monolayer of dog cardiac myosin.
It is clearly seen that 111In-labeled mon2G4-lipo-
somes bind to the monolayer of myosin 20^25 times
better than control protein-free 111In-pNP-PEG-
DOPE-liposomes (after the complete hydrolysis of
pNP groups) and non-speci¢c 111In-labeled
mon2C5-pNP-PEG-DOPE-liposomes. 111In-Labeled
plain PC:Chol liposomes demonstrated background
binding on the level of pNP-PEG-DOPE-liposomes.
The preincubation of the monolayer with an excess
of free mon2G4 completely abolished the binding of
mon2G4-liposomes (data not shown). These results
clearly evidence the preservation of antibody-speci¢c
activity towards the antigen after covalent coupling
to the distal ends of polymer chains of PEG-lipo-
somes via pNP groups.
The comparison of two di¡erent protocols of anti-
body immobilization (see the results of the ELISA
experiment in Fig. 8) shows that, at the intermediate
PEG concentration used (6 mol% of total lipid),
there is a very small di¡erence in the activity of
two di¡erent PEG-immunoliposomes (compare
curves 2 and 3), and both preparations, in terms of
their immunoreactivity, do not di¡er much from the
preparation of polymer-free liposomes containing the
same quantity of membrane-incorporated NGPE-
mon2G4. Still, the attachment of the antibody via
pNP groups does not require any preliminary chem-
ical modi¢cation of the antibody and makes the
whole coupling procedure more simple and speedy.
3.6. Activity of liposome-bound mon2C5; e¡ect of
PEG quantity
The bene¢t of pNP-mediated attachment of anti-
bodies to the distal ends of liposome-grafted polymer
chains over NGPE-mediated membrane incorpora-
tion at high concentrations of the liposomal PEG
was shown in experiments involving antinucleosome
mon2C5. The ELISA data presented in Fig. 9 clearly
show that when NGPE-modi¢ed mon2C5 is co-in-
corporated into the liposomal membrane together
with PEG-DOPE, the antigen-binding activity of
the liposomal antibody gradually decreases with the
increase in the concentration of PEG-DOPE (com-
pare curves 1^5 for liposomes with 0^15 mol% of
PEG-DOPE). At 15 mol% PEG-DOPE, mon2C5
binding with nucleosomes is completely abolished
Fig. 7. 1, binding of 111In-labeled mon2G4-pNP-PEG-DOPE-
liposomes with a monolayer of the antigen (dog cardiac myo-
sin). Controls: 2, binding of protein-free 111In-pNP-PEG-
DOPE-liposomes (after the complete hydrolysis of pNP groups)
on a myosin monolayer; 3, binding of 111In-labeled mon2C5-
pNP-PEG-DOPE-liposomes on a myosin monolayer. See Sec-
tion 2.2 for details.
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because of steric hindrances created by neighboring
polymeric chains [8,9,29,30]. The data correspond
well to the observations made in [31,32]. However,
if the antibody was attached to liposomes containing
the same high concentration of PEG-DOPE via co-
valent coupling to the distal ends of polymeric chains
via pNP groups (in this case liposomes contained 15
mol% of a 5:1 mixture of PEG-DOPE and pNP-
Fig. 8. ELISA results for various preparations of liposome-bound antimyosin mon2G4. 1, NGPE-mon2G4 incorporated into the
membrane of PC:Chol liposomes; 2, mon2G4 immobilized on the distal ends of polymer chains of pNP-PEG-DOPE-liposomes (poly-
mer concentration 6 mol% of total lipids) ; 3, NGPE-mon2G4 co-incorporated into PC:Chol liposomes together with 6 mol% of
PEG-DOPE. See Section 2.2 for details.
Fig. 9. ELISA results for various preparations of liposome-bound antinucleosome mon2C5. 1, NGPE-mon2C5 in PC:Chol liposomes
without PEG; 2, as in (1) with 2 mol% PEG-DOPE; 3, as in (1) with 8 mol% PEG-DOPE; 4, as in (1) with 11 mol% PEG-DOPE;
5, as in (1) with 15 mol% PEG-DOPE; 6, unmodi¢ed mon2C5 covalently attached (with active site protection) via pNP groups to
liposomes containing 15 mol% pNP-PEG-DOPE. See Section 2.2 for details.
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PEG-DOPE), rather than by NGPE-mediated mem-
brane incorporation, antibody activity was preserved
to a very high extent (see curve 6 in Fig. 8). Thus,
this fast and simple method of ligand attachment to
the distal ends of liposome-grafted polymer chains
developed by us permits the preservation of the spe-
ci¢c activity of the immobilized ligand even with high
concentrations of the protecting polymer. The data
are in good agreement with earlier published obser-
vations involving more complex methods of antibody
attachment to the distal ends of liposome-grafted
polymers [31^37].
3.7. Stability of liposomes in mouse serum
Earlier, it was repeatedly shown that the attach-
ment of amphiphilic PEG derivatives to the liposome
surface does not cause leakage of a marker or drug
from liposomes both in vitro and in vivo (see, for
example, the early data in [20] and the recent ¢ndings
in [55]). In the latter study, a successful targeting of
doxorubicin entrapped in antibody-targeted PEG-
liposomes to human myeloma cells in vitro and ex
vivo was demonstrated with the drug being retained
inside liposomes. Since the preparation of pNP-PEG-
DOPE-containing liposomes follows standard proce-
dures, and the reactive PEG derivative described here
rapidly converts into a ‘usual’ liposome surface-at-
tached PEG, one can hardly expect any abnormal-
ities in the liposome stability both in vitro and in
vivo compared to other PEG- or reactive-PEG-lipo-
somes. Since the principal subject of our study is the
development of new ligand attachment chemistry to
PEG-liposomes, detailed in vivo studies are beyond
the scope of this paper and constitute the subject of
our ongoing investigation.
However, in order to additionally con¢rm the lipo-
some stability and ability to retain an intraliposomal
load (model drug), we have investigated the e¡ect of
mouse serum on the £uorescent dye (calcein) release
from liposomes of di¡erent composition used in our
experiments as well as from control liposomes. Pre-
liminarily, it was shown that in the absence of serum,
all liposomes used in these experiments do not re-
lease more than 2^4% of entrapped calcein after in-
cubation in HBS for 20 h (data not shown, variations
from sample to sample were insigni¢cant). In the
presence of mouse serum, however, the ability of
liposomes to retain the entrapped £uorescent dye
strongly depends on their composition.
The data presented in Fig. 10 clearly demonstrate
that, in the presence of serum, calcein release pro-
ceeds at a high rate from plain PC:Chol liposomes
(control) and liposomes containing small quantities
of attached polymer or polymer-to-ligand conjugate,
approx. 0.5 mol% of pNP-PEG-DOPE or mon2C5-
pNP-PEG-DOPE (all pNP group-containing samples
were preliminarily incubated for 2 h at pH 7.5 to
hydrolyze free pNP groups). Still, in the last two
cases the calcein release is somewhat slower, prob-
ably because of the partial steric protection still pro-
vided even with a small quantity of the attached
polymer (or polymer-to-protein conjugate). At the
same time, liposomes with 6 mol% of pNP-PEG-
DOPE or mon2C5-PEG-DOPE demonstrate
strongly inhibited calcein release very similar to
that from sterically stabilized liposomes containing
6 mol% of PEG-PE (control). This result con¢rms
a ‘normal’ protecting e¡ect of pNP-PEG-DOPE, as
well as the biological stability of pNP-PEG-DOPE-
liposomes and their ability to retain the entrapped
Fig. 10. The release of the £uorescent dye calcein from lipo-
somes of various composition in the presence of 50% mouse se-
rum. 1, plain PC:Chol liposomes; and liposomes with: 2, 0.5
mol% of pNP-PEG-DOPE; 3, 0.5 mol% mon2C5-pNP-PEG-
DOPE; 4, 6 mol% of pNP-PEG-DOPE; 5, 6 mol% of
mon2C5-pNP-PEG-DOPE; 6, 6 mol% of PEG-DOPE. See Sec-
tion 2.2 for details.
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compound (which might be considered a model
drug).
4. Conclusion
A new amphiphilic PEG derivative, pNP-PEG-PE,
is introduced, which easily incorporates into the lipo-
somal membrane via its phospholipid residue and
easily binds any amino group-containing ligands
via its water-exposed pNP group. The reaction be-
tween the pNP group and ligand amino group pro-
ceeds easily and quantitatively at pH around 8, and
remaining free pNP groups are easily eliminated by
spontaneous hydrolysis. pNP-PEG-PE provides an
easy and convenient tool for protein attachment to
the distal ends of liposome-grafted PEG chains.
pNP-PEG-PE-containing liposomes are able to bind
substantial quantities of proteins via pNP groups
located on the distal ends of PEG chains. Lectins,
avidin, and antibodies bound with liposomes via
pNP-PEG-PE retain their speci¢c activity, even at
high concentrations of liposome-grafted polymer.
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